Drug profile · INN
palonosetron hydrochloride
PALONOSETRON HYDROCHLORIDE
palonosetron hydrochloride (PALONOSETRON HYDROCHLORIDE) is a serotonin 3a (5-ht3a) receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — palonosetron hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 1
- Data quality
- 0.89
Quick answer
palonosetron hydrochloride (PALONOSETRON HYDROCHLORIDE) is a serotonin 3a (5-ht3a) receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 3a (5-HT3a) receptor antagonist
Primary target: 5-hydroxytryptamine receptor 3A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is palonosetron hydrochloride?
palonosetron hydrochloride (PALONOSETRON HYDROCHLORIDE) is a serotonin 3a (5-ht3a) receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for palonosetron hydrochloride?
PALONOSETRON HYDROCHLORIDE is a marketed brand name for palonosetron hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of palonosetron hydrochloride?
palonosetron hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.